Source: http://www.scribd.com/doc/101258971/Galderma-Laboratories-et-al-v-Watson-Pharmaceuticals-et-al
Timestamp: 2015-05-25 02:41:20
Document Index: 732766988

Matched Legal Cases: ['Application No. 022320', '§ 1331', '§ 1391', 'Application No. 204067', '§271', '§ 355']

P. 1Galderma Laboratories et. al. v. Watson Pharmaceuticals et. al.Galderma Laboratories et. al. v. Watson Pharmaceuticals et. al.Ratings: (0)|Views: 150|Likes: 0Published by PriorSmartOfficial Complaint for Patent Infringement in Civil Action No. None: Galderma Laboratories, L.P. et. al. v. Watson Pharmaceuticals, Inc. et. al. Filed in U.S. District Court for the Northern District of Texas, no judge yet assigned. See http://news.priorsmart.com/-l6sD for more info.Official Complaint for Patent Infringement in Civil Action No. None: Galderma Laboratories, L.P. et. al. v. Watson Pharmaceuticals, Inc. et. al. Filed in U.S. District Court for the Northern District of Texas, no judge yet assigned. See http://news.priorsmart.com/-l6sD for more info.More info:Categories:Types, Business/Law, Court FilingsPublished by: PriorSmart on Jul 27, 2012Copyright:Public DomainAvailability:Read on Scribd mobile: iPhone, iPad and Android.download as PDF, TXT or read online from ScribdFlag for inappropriate content|Add to collectionSee moreSee lesshttps://www.scribd.com/doc/101258971/Galderma-Laboratories-et-al-v-Watson-Pharmaceuticals-et-al02/01/2013pdftextoriginal C
1IN THE UNITED STATES DISTRICT COURTFOR THE NORTHERN DISTRICT OF TEXASDALLAS DIVISIONGALDERMA LABORATORIES, L.P.,GALDERMA S.A., andGALDERMA RESEARCH &DEVELOPMENT, S.N.C.,Plaintiffs,v.WATSON PHARMACEUTICALS, INC.and WATSON LABORATORIES, INC.Defendants.§§§§§§§§§§§§§ CIVIL ACTION NO. ______________COMPLAINT FOR PATENT INFRINGEMENT
Plaintiffs, GALDERMA LABORATORIES, L.P., GALDERMA S.A., and GALDERMARESEARCH & DEVELOPMENT, S.N.C., file this Complaint for Patent Infringement againstDefendants WATSON PHARMACEUTICALS, INC. and WATSON LABORATORIES, INC.and state:
Galderma Laboratories, L.P. ("Galderma L.P.") is a Texas limited partnershipwith its principal place of business at 14501 North Freeway, Fort Worth, Texas 76177.Galderma L.P. is the beneficial holder of rights to market Epiduo
(adapalene and benzoyl peroxide) Gel, 0.1% / 2.5% (hereafter "Epiduo
Gel") under U.S. Food and Drug Administration("FDA") approval of New Drug Application No. 022320, approved December 8, 2008.Galderma L.P. has the exclusive right from Galderma R&D to distribute Epiduo
Gel in theUnited States. Epiduo
Gel is a topical ointment prescription drug that combines a retinoid
(adapalene) and an antimicrobial (benzoyl peroxide) for the treatment of acne vulgaris (severeacne) in people who are at least 12 years old.2.
Galderma S.A. is a Swiss company with its principal place of business at WorldTrade Center, Avenue de Gratta-Paille 2, 1018 Lausanne, Switzerland. Galderma S.A. isinvolved in the research, development, marketing, and/or sale of pharmaceutical products.3.
Galderma Research & Development, S.N.C. ("Galderma R&D") is a Frenchcorporation with its principal place of business at 2400 Route Des Colles, Les Templiers, Biot,France 06410. Galderma R&D is the current owner of U.S. Patent No. 8,071,644 (the "'644Patent"), U.S. Patent No. 8,080,537 (the "'537 Patent"), and U.S. Patent No. 8,129,362 (the "'362Patent"). A copy of the '644 Patent is attached as Exhibit "A." A copy of the '537 Patent isattached as Exhibit "B." A copy of the '362 Patent is attached as Exhibit "C."4.
Watson Pharmaceuticals, Inc. ("Watson") is a Nevada corporation with its principal place of business at 400 Interpace Parkway, Parsippany, New Jersey 07054. Watsondevelops, manufactures, and markets generic versions of branded pharmaceutical productsthrough various operating subsidiaries, including Defendant Watson Laboratories, Inc. Watsonmay be served with process by and through its registered agent for service of process, CTCorporation System, 818 West Seventh Street, Los Angeles, California 90017.5.
Watson Laboratories, Inc. ("Watson Labs") is a Nevada corporation with its principal place of business at 311 Bonnie Circle, Corona, California 92880. Watson Labs is awholly-owned subsidiary of Watson Pharmaceuticals, Inc. On information and belief, WatsonLabs is in the business of, among other things, developing, manufacturing and selling genericversions of branded pharmaceutical products for the U.S. Market. Watson Labs may be served
with process by and through its registered agent for service of process, CT Corporation System,818 West Seventh Street, Los Angeles, California 90017.6.
Watson and Watson Labs have common officers and directors. On informationand belief, Watson directed, authorized, participated in, assisted, and cooperated with WatsonLabs in all of the acts complained of herein. On information and belief, Watson Labs is the alter-ego of Watson and/or is controlled by and/or is an agent of Watson with respect to actscomplained of herein. Watson Pharmaceuticals, Inc. and Watson Laboratories, Inc. arecollectively referred to herein as "Defendants."
This is a complaint for patent infringement. This Court has jurisdiction over thesubject matter of the claims asserted pursuant to 28 U.S.C. §§ 1331 and 1338(a). Venue in thisCourt is proper under 28 U.S.C. §§ 1391 and 1400(b).8.
This Court has personal jurisdiction over Defendants because Defendantsmanufacture and/or sell products for distribution throughout the United States and, oninformation and belief, regularly conduct business in the State of Texas. On information and belief, Watson and Watson Labs acted in concert to prepare and submit Abbreviated New DrugApplication No. 204067 (the "ANDA") to the FDA (an act of infringement under 35 U.S.C. §271(e)(2)), including a certification under 21 U.S.C. § 355(j)(2)(A)(vii)(IV) (the "Paragraph IVCertification")
the acts which give rise to the instant litigation
with knowledge that GaldermaL.P. would be injured by such actions in this district.9.
Defendants submitted the ANDA seeking approval from the FDA to engage in thecommercial manufacture, use, and sale of generic Adapalene and Benzoyl Peroxide Gel, 0.1% /2.5% ("the Accused Product") prior to the expiration of,
the '644 Patent, '537 Patent,